Skip to main content

Breadcrumb

  1. Home

Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

Valid for Measure Submission
Valid for Initial Endorsement
Valid for Maintenance

Appropriate Treatment for Children With Upper Respiratory Infection (URI)

  • The Appropriate Treatment for Upper Respiratory Infection (URI) measure assesses whether members 3 months of age and older with a diagnosis of upper respiratory infection were not dispensed an antibiotic prescription. The measure includes patients enrolled in commercial, Medicaid, and Medicare health plans.

    CBE ID
    0069

Aspirin at Arrival

  • Percentage of emergency department acute myocardial infarction (AMI) patients or chest pain patients (with Probable Cardiac Chest Pain) without aspirin contraindications who received aspirin within 24 hours before ED arrival or prior to transfer.

    CBE ID
    0286

Assessment of Health-related Quality of Life in Dialysis Patients

  • Percentage of eligible dialysis patients who complete a health-related quality of life assessment with or without assistance using the KDQOL-36 (36-question survey that assesses patients´ functioning and well-being) at least once during a calendar year.

    CBE ID
    0260

Asthma Admission Rate (PDI 14)

  • Admissions with a principal diagnosis of asthma per 100,000 population, ages 2 through 17 years. Excludes cases with a diagnosis code for cystic fibrosis and anomalies of the respiratory system, obstetric admissions, and transfers from other institutions.

    [NOTE: The software provides the rate per population. However, common practice reports the measure as per 100,000 population. The user must multiply the rate obtained from the software by 100,000 to report admissions per 100,000 population.]

    CBE ID
    0728

Asthma Medication Ratio

  • The percentage of patients 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

    CBE ID
    1800

Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy

  • Percentage of patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation (AF) or atrial flutter whose assessment of the specified thromboembolic risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS2 risk stratification, who are prescribed warfarin OR another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism

    CBE ID
    1525